PAREXEL International Corporation (PRXL) Upgraded to “Mkt Perform” by Raymond James Financial, Inc.

PAREXEL International Corporation (NASDAQ:PRXL) was upgraded by equities research analysts at Raymond James Financial, Inc. from an “underperform” rating to a “mkt perform” rating in a report released on Tuesday, Marketbeat Ratings reports.

Other research analysts also recently issued reports about the company. Mizuho boosted their price target on PAREXEL International Corporation from $66.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, May 30th. Zacks Investment Research raised shares of PAREXEL International Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, April 5th. Credit Suisse Group reissued a “neutral” rating and set a $83.00 price objective (up from $65.00) on shares of PAREXEL International Corporation in a research note on Tuesday, June 6th. Goldman Sachs Group, Inc. (The) raised shares of PAREXEL International Corporation from a “sell” rating to a “neutral” rating and boosted their price objective for the company from $63.00 to $77.00 in a research note on Tuesday, May 23rd. Finally, Evercore ISI raised shares of PAREXEL International Corporation from an “in-line” rating to an “outperform” rating and set a $85.00 price objective for the company in a research note on Monday, May 15th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $72.83.

Analyst Recommendations for PAREXEL International Corporation (NASDAQ:PRXL)

PAREXEL International Corporation (PRXL) traded up 3.94% during midday trading on Tuesday, hitting $87.23. The stock had a trading volume of 7,844,617 shares. The firm has a market cap of $4.43 billion, a P/E ratio of 38.34 and a beta of 0.80. The stock has a 50-day moving average price of $78.07 and a 200 day moving average price of $68.38. PAREXEL International Corporation has a 12-month low of $51.16 and a 12-month high of $87.45.

PAREXEL International Corporation (NASDAQ:PRXL) last issued its quarterly earnings results on Wednesday, May 3rd. The medical research company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The company had revenue of $529.30 million during the quarter, compared to the consensus estimate of $529.38 million. PAREXEL International Corporation had a return on equity of 28.68% and a net margin of 5.12%. PAREXEL International Corporation’s revenue was up .4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.89 EPS. On average, equities analysts anticipate that PAREXEL International Corporation will post $3.24 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.thestockobserver.com/2017/06/20/parexel-international-corporation-prxl-upgraded-by-raymond-james-financial-inc-to-market-perform.html.

A number of institutional investors have recently bought and sold shares of the stock. Thrivent Financial for Lutherans boosted its position in PAREXEL International Corporation by 10.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 9,130 shares of the medical research company’s stock worth $600,000 after buying an additional 860 shares during the last quarter. Bowling Portfolio Management LLC purchased a new position in PAREXEL International Corporation during the fourth quarter worth $565,000. Ladenburg Thalmann Financial Services Inc. boosted its position in PAREXEL International Corporation by 1.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,552 shares of the medical research company’s stock worth $431,000 after buying an additional 84 shares during the last quarter. AQR Capital Management LLC boosted its position in PAREXEL International Corporation by 160.4% in the fourth quarter. AQR Capital Management LLC now owns 237,673 shares of the medical research company’s stock worth $15,620,000 after buying an additional 146,398 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in PAREXEL International Corporation by 6.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 14,569 shares of the medical research company’s stock worth $957,000 after buying an additional 903 shares during the last quarter. 97.69% of the stock is owned by institutional investors.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply